<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="175872">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00806117</url>
  </required_header>
  <id_info>
    <org_study_id>SYSU50102008049</org_study_id>
    <nct_id>NCT00806117</nct_id>
  </id_info>
  <brief_title>Comparison of Post-surgery Adjuvant Therapy for Cervical Carcinoma</brief_title>
  <official_title>Comparison of Different Adjuvant Treatments Following Radical Surgery in Early Stage Cervical Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Guangdong Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shenzhen People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer Hospital of Guangxi Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cervical cancer is still the most common gynecologic cancer. There was no obvious increase
      of the survival over years. The risk of recurrence after radical surgery has increased with
      positive lymph nodes, positive surgical margins, positive lymphatic vascular space and deep
      invasion of the cervical stroma. In recent years, the role of chemotherapy for cervical
      cancer has been gradually recognized. But as a adjuvant therapy post-surgery, if
      chemotherapy can improve the overall survival rate of patients with adverse pathological
      prognostic factors is inconclusive.

      In this study, in order to investigate the effect and adverse reaction of chemotherapy as
      the adjuvant therapy post-surgery on patients with adverse pathological prognostic factors,
      nine hundred and ninety patients will be randomly divided into three groups, comparing
      radiotherapy alone, concurrent chemoradiation and sequence chemotherapy and radiotherapy (2
      cycles chemotherapy of Paclitaxel and Cisplatin before and after the irradiation). The
      investigators aim to find out the best therapeutic regimen with lowest adverse reaction for
      cervical cancer with adverse pathological prognostic factors. To guide clinical treatment
      options.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After radical surgery, patients with stage IB1 to IIA2 cervical cancer who had one or more
      following pathological factors were recruited: lymph node metastases (LNM), positive
      parametrium or margins (PPM), lymphatic vascular space involvement (LVSI), deep invasion of
      cervical stromal (DIS). Eligible patients were randomized to three groups. Group A underwent
      50 GY RT alone. Group B received concurrent weekly cisplatin and RT. Group C received
      paclitaxel and bolus cisplatin every three weeks for two cycles before RT, followed by two
      cycles.

      We have recruited 800 patients till November 2014.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single Blind (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease Free Survival</measure>
    <time_frame>3-Yr</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>5-Yr</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">990</enrollment>
  <condition>Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>Radiotherapy (RT)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Radiotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Concurrent chemoirradiation (CCRT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Concurrent chemoirradiation:
External beam radiation with concurrent weekly platinum chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence chemo and radiation (SCRT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sequence chemotherapy and radiotherapy:
2 cycles chemotherapy of Paclitaxel and Cisplatin before and after the irradiation</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy (RT)</intervention_name>
    <description>External irradiation 50Gy/5 weeks
Lateral: 2 cm lateral to the bony margin of the pelvis
Superior: Between L5 and S1
Inferior: 2 cm below the obturator foramen Intracavitary boost 30-35Gy/4 weeks(positive vaginal margins only)</description>
    <arm_group_label>Radiotherapy (RT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Concurrent chemoirradiation (CCRT)</intervention_name>
    <description>Cisplatin 40mg/m2 every week during external irradiation</description>
    <arm_group_label>Concurrent chemoirradiation (CCRT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sequence chemotherapy and radiotherapy (SCRT)</intervention_name>
    <description>Paclitaxel 135~175mg/m2 over 3 hours Cisplatin 60~75mg/m2</description>
    <arm_group_label>Sequence chemo and radiation (SCRT)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with newly histologically confirmed cervical carcinoma

          -  Original clinical stage must be Ib~IIa （FIGO）

          -  Age between 18-65

          -  With the presence of these four factors after radical surgery:(1)positive lymph
             nodes,(2)positive parametria, or positive surgical margins,(3)positive lymphatic
             vascular space,(4)outer one-third invasion of the cervical stroma

          -  More than 3 months survival is to expect

          -  Patients must give signed informed consent

        Exclusion Criteria:

          -  The presence of uncontrolled life-threatening illness

          -  Receiving other ways of anti-cancer therapy

          -  Residual tumor which can not be removed in the surgery

          -  Investigator consider the patients can't finish the whole study

          -  With normal liver function test (ALT、AST&gt;2.5×ULN)

          -  With normal renal function test (Creatinine&gt;1.5×ULN)

          -  WBC&lt;4,000/mm3 or PLT&lt;100,000/mm3

          -  Receive the external pelvic irradiation before the surgery
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jihong Liu, Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jihong Liu, Ph.D.</last_name>
    <phone>86-20-8734-3102</phone>
    <email>Liujih@mail.sysu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>He Huang, Ph.D.</last_name>
    <phone>86-20-8734-3104</phone>
    <email>huangh@sysucc.org.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Gynecologic Oncology, Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jihong Liu, Ph.D.</last_name>
      <phone>86-20-87343102</phone>
      <email>Liujih@mail.sysu.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>He Huang, Ph.D.</last_name>
      <phone>86-20-87343104</phone>
      <email>huangh@sysucc.org.cn</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <lastchanged_date>March 13, 2016</lastchanged_date>
  <firstreceived_date>December 8, 2008</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Jihong Liu</investigator_full_name>
    <investigator_title>Department of Gynecologic Oncology, Sun Yat-sen University Cancer Center</investigator_title>
  </responsible_party>
  <keyword>Cervical cancer</keyword>
  <keyword>Concurrent chemoradiation</keyword>
  <keyword>Randomized controlled clinical trials</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
